Developing a Randomised Efficacy PREcision medicine Platform trial design for Cavernomas: the CARE PREP study

Background Symptomatic cerebral cavernous malformations are a rare sporadic or familial disease, which may cause haemorrhagic strokes or epileptic seizures. In 2015, a James Lind Alliance Priority Setting Partnership ranked targeted drug therapies as fourth of the top 10 research priorities for cere...

Full description

Bibliographic Details
Published in:Efficacy and Mechanism Evaluation
Main Authors: Rustam Al-Shahi Salman, Kasia Adamczuk, Richard A Parker, Christopher J Weir, Roberto Latini, Helen Kim, David White, Helen Evans, Jana Bergholtz, Cornelia Lee, Carlos Casaus
Format: Article
Language:English
Published: NIHR Journals Library 2025-03-01
Subjects:
haemangioma
cavernous
central nervous system
humans
animals
sample size
propranolol
consensus
leadership
aspirin
feasibility studies
seizures
phenotype
biomarkers
randomised controlled trials as topic
Online Access:https://doi.org/10.3310/TYUP6982

Internet

https://doi.org/10.3310/TYUP6982

Similar Items